Mymd Pharmaceuticals Inc (MYMD)

$1.82

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.78
    $1.84
    $1.82
    downward going graph

    2.19%

    Downside

    Day's Volatility :3.25%

    Upside

    1.08%

    downward going graph
  • $1.75
    $63.90
    $1.82
    downward going graph

    3.85%

    Downside

    52 Weeks Volatility :97.26%

    Upside

    97.15%

    downward going graph

Returns

PeriodMymd Pharmaceuticals IncIndex (Russel 2000)
3 Months
-35.92%
0.0%
6 Months
-61.28%
0.0%
1 Year
-94.72%
0.0%
3 Years
-98.73%
-20.2%

Highlights

Market Capitalization
4.3M
Book Value
$4.54
Earnings Per Share (EPS)
-9.27
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-50.46%
Return On Equity TTM
-101.36%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-28.2M
Diluted Eps TTM
-9.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Mymd Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Technicals Summary

Sell

Neutral

Buy

Mymd Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
-3.7%
-61.28%
-94.72%
-98.73%
-98.64%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
NA
NA
NA
0.0
-1.01
-0.5
NA
4.54
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc
Buy
$4.3M
-98.64%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Mymd Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 156.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 285.2%

Institutional Holdings

  • Mirae Asset Global Investments (Korea) Co Ltd

    37.96%

  • Vanguard Group Inc

    1.33%

  • BlackRock Inc

    0.29%

  • UBS Group AG

    0.09%

  • Bridgecreek Investment Management, LLC

    0.04%

  • Parallel Advisors, LLC

    0.04%

Company Information

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.

Organization
Mymd Pharmaceuticals Inc
Employees
6
CEO
Dr. Christopher C. Chapman Jr., M.D.
Industry
Miscellaneous

Discover More

FAQs